| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Editorials |
NCI/FDA Clinical Proteomics Program, Office of the Director, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892
NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892
aAuthor for correspondence.
| The first 20% of the full text of this article appears below. |
Advances in mass spectrometry-based diagnostics could ignite a revolution in the field of molecular medicine. This platform has the potential to become the practical clinical analyzer of the future for nucleic acids and proteins. Mass spectrometry-based diagnostics are an example of a "disruptive" or "nonlinear" technology (1)(2). Such disruptive technologies are by their very nature polarizing, causing a dynamic dichotomy of excitement (3) as well as anxiety(4) in the clinical diagnostic community because this technology can potentially outperform traditional measurement and detection systems. In this issue of Clinical Chemistry, Bonk et al. (5) demonstrate the advantages of mass spectrometry compared with traditional electrophoretic methodologies. Bonk et al. used mass spectrometry as a "sensor" to detect the amplified product from a PCR amplification reaction. The ultimate clinical application for this study is the early detection of colon cancer, a topic of obvious public health importance.
Although major advances have been made in elucidating the genetic underpinnings of cancer, especially colorectal cancer, diagnostic methodologies for routine clinical detection and monitoring of important cancer genetic derangements have lagged behind. Microsatellite instability (MSI), caused by mismatch repair gene silencing, is predicted to be an important early event in cancer progression (6)(7)(8).
In this issue, Bonk et al.
(5) report on a study in which they use time-of-flight-based mass spectrometry to detect MSI. Unlike previous studies, in which chromatography, electrophoresis, and traditional DNA sequencing methodologies were used to detect the presence of
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  Y. Saeys, I. Inza, and P. Larranaga A review of feature selection techniques in bioinformatics Bioinformatics, October 1, 2007; 23(19): 2507 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shen, C. Behrens, I. I. Wistuba, L. Feng, J. J. Lee, W. K. Hong, and R. Lotan Identification and Validation of Differences in Protein Levels in Normal, Premalignant, and Malignant Lung Cells and Tissues Using High-Throughput Western Array and Immunohistochemistry Cancer Res., December 1, 2006; 66(23): 11194 - 11206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Serum Proteomic Profiling by Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry for Cancer Diagnosis: Next Steps Cancer Res., June 1, 2006; 66(11): 5540 - 5541. [Full Text] [PDF]
|
|
|
|
|
|
N. Jeffries Algorithms for alignment of mass spectrometry proteomic data Bioinformatics, July 15, 2005; 21(14): 3066 - 3073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Yu, S. Ongarello, R. Fiedler, X. W. Chen, G. Toffolo, C. Cobelli, and Z. Trajanoski Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data Bioinformatics, May 15, 2005; 21(10): 2200 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Listgarten and A. Emili Statistical and Computational Methods for Comparative Proteomic Profiling Using Liquid Chromatography-Tandem Mass Spectrometry Mol. Cell. Proteomics, April 1, 2005; 4(4): 419 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Hortin Can Mass Spectrometric Protein Profiling Meet Desired Standards of Clinical Laboratory Practice? Clin. Chem., January 1, 2005; 51(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
D. Radulovic, S. Jelveh, S. Ryu, T. G. Hamilton, E. Foss, Y. Mao, and A. Emili Informatics Platform for Global Proteomic Profiling and Biomarker Discovery Using Liquid Chromatography-Tandem Mass Spectrometry Mol. Cell. Proteomics, October 1, 2004; 3(10): 984 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Geho, E. F. Petricoin, and L. A. Liotta Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer: Commentary re S. A. Schwartz et al., Protein Profiling in Brain Tumors Using Mass Spectrometry: Feasibility of a New Technique for the Analysis of Protein Expression. Clin. Cancer Res., 10: 981-987, 2004. Clin. Cancer Res., February 1, 2004; 10(3): 825 - 827. [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Petricoin, V. Rajapaske, E. H. Herman, A. M. Arekani, S. Ross, D. Johann, A. Knapton, J. Zhang, B. A. Hitt, T. P. Conrads, et al. Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection Toxicol Pathol, January 1, 2004; 32(1_suppl): 122 - 130. [Abstract] [PDF]
|
|
|
|
|
|
E. Petricoin III and L. A. Liotta The Vision for a New Diagnostic Paradigm Clin. Chem., August 1, 2003; 49(8): 1276 - 1278. [Full Text] [PDF]
|
|
|
|
|
|
D. H. Chace, E. F. Petricoin, and L. A. Liotta Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection Has Already Arrived * Drs. Petricoin and Liotta respond: Clin. Chem., July 1, 2003; 49(7): 1227 - 1229. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
